Luís Fernando Bouzas

Centro Universitário de Volta Redonda

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Afonso Celso Vigorito

Universidade Estadual de Campinas (UNICAMP)

Adriana Seber

Universidade Federal de São Paulo

Mary E.D. Flowers

Fred Hutch Cancer Center

Ricardo Chiattone

Hospital Samaritano de São Paulo

Vaneuza Araújo Moreira Funke

Universidade Federal do Paraná

Maria Cláudia Rodrigues Moreira

Instituto Nacional do Câncer

Rita de Cássia Tavares

Instituto Nacional do Câncer

Liane Esteves Daudt

Hospital de Clínicas de Porto Alegre

Carmem Bonfim

Hospital de Clínicas Universidade Federal do Paraná

George Maurício Navarro Barros

Hospital de Câncer de Barretos

Cooperative Institutions

Instituto Nacional do Câncer

Universidade Federal do Rio de Janeiro

Universidade de São Paulo

Hospital Israelita Albert Einstein

Instituto Nacional del Cáncer

Hospital de Clínicas Universidade Federal do Paraná

Universidade Federal de São Paulo

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Universidade Federal do Paraná

Universidade do Estado do Rio de Janeiro

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Hematopoietic Stem Cell Transplantation<subtitle>A Global Perspective</subtitle>

JAMA (2010)

Aloïs Gratwohl Helen Baldomero Mahmoud Aljurf Marcelo C. Pasquini Luís Fernando Bouzas

Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known about HSCT use and the factors associated with it on a global level.To determine current use of HSCT to assess differences in its application and to explore associations of macroeconomic factors with transplant rates on a global level.Retrospective survey study of patients receiving allogeneic and autologous HSCTs for 2006 collected by 1327 centers in 71 participating countries of the Worldwide Network for Blood and Marrow Transplantation. The regional areas used herein are (1) the Americas (the corresponding World Health Organization regions are North and South America); (2) Asia (Southeast Asia and the Western Pacific Region, which includes Australia and New Zealand); (3) Europe (includes Turkey and Israel); and (4) the Eastern Mediterranean and Africa.Transplant rates (number of HSCTs per 10 million inhabitants) by indication, donor type, and country; description of main differences in HSCT use; and macroeconomic factors of reporting countries associated with HSCT rates.There were 50 417 first HSCTs; 21 516 allogeneic (43%) and 28 901 autologous (57%). The median HSCT rates varied between regions and countries from 48.5 (range, 2.5-505.4) in the Americas, 184 (range, 0.6-488.5) in Asia, 268.9 (range, 5.7-792.1) in Europe, and 47.7 (range, 2.8-95.3) in the Eastern Mediterranean and Africa. No HSCTs were performed in countries with less than 300,000 inhabitants, smaller than 960 km(2), or having less than US $680 gross national income per capita. Use of allogeneic or autologous HSCT, unrelated or family donors for allogeneic HSCT, and proportions of disease indications varied significantly between countries and regions. In linear regression analyses, government health care expenditures (r(2) = 77.33), HSCT team density (indicates the number of transplant teams per 1 million inhabitants; r(2) = 76.28), human development index (r(2) = 74.36), and gross national income per capita (r(2) = 74.04) showed the highest associations with HSCT rates.Hematopoietic stem cell transplantation is used for a broad spectrum of indications worldwide, but most frequently in countries with higher gross national incomes, higher governmental health care expenditures, and higher team densities.

10.1001/jama.2010.491

Cite

Citations (608)

Current use and outcomes of hematopoietic stem cell transplantation: Brazilian summary slides - 2023

JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (2023)

Anderson João Simione Heliz Regina A. Neves Cinthya Corrêa da Silva Paula Moreira da Silva Sabaini Bruna Letícia da Silva Santos Geraldo

The first hematopoietic stem cell transplantation (HSCT) program in Latin America started in 1979 at the federal university hospital in Curitiba, Paraná, Brazil. Over the years, the number of centers performing transplants in our country has increased tremendously, generating the need to know the results of this treatment modality. Understanding the HSCT scenario in Brazil is still challenging, since not all Brazilian centers report data to the Center for International Blood and Marrow Research (CIBMTR). Despite the improvement in the number of reporting centers over the past few years, infrastructure and trained data managers are still lacking. The partnership between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the CIBMTR enabled the establishment of the Hematopoietic Stem Cell Transplantation Brazilian Registry (HSCTBR), using the CIBMTR Data Back to Center (DBtC) tool to retrieve Brazilian HSCT data in a standardized and organized way. Since then, it has been possible to gather country-level data on HSCT demographics and transplant outcomes. Between 2012 and 2022, complete information on 9,868 transplants were reported to the CIBMTR from 40 Brazilian transplant centers. The consolidation of the HSCTBR using CIBMTR infrastructure allowed the development and regular update of the Brazilian Summary Slides. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (US) Summary Slides. In this paper we present the 2023 SBTMO-CIBMTR Summary Slides prepared by the SBTMO data managers (GD-SBTMO).

Bone transplantation

10.46765/2675-374x.2023v4n2p200

Cite

Citations (0)

Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients

European Journal Of Haematology (2015)

Paulo Vidal Campregher Nelson Hamerschlak Vergílio Antônio Renzi Colturato Marcos Augusto Mauad Mair Pedro de Souza

The objective of this study was to compare the major transplant outcomes between patients receiving hematopoietic stem cell transplantation (HSCT) from bone marrow (BM) or peripheral blood stem cells (PBSC).All consecutive HSCT patients using BM or PBSC from an HLA-matched related donors for haematological malignancies after high intensity conditioning at seven Brazilian transplant centres between January 2008 and December 2009 were retrospectively evaluated.In the study period, 334 patients were treated in the centres and included in the evaluation. The cumulative incidence of grades II-IV and III-IV acute graft-versus-host disease (GVHD) at one year was 36.7% and 9.7% for BM recipients and 34.4% and 15.1% for PBSC recipients, respectively (not statistically different). The cumulative incidence of chronic GVHD at three years was 53.7% and 79.8% (HR 1.93; 95% CI 1.38-2.69, P < 0.001) for BM and PBSC, respectively. Median overall survival was 2.85 and 2.39 years for BM and PBSC recipients, respectively (HR 1.19; 95% CI, 0.84-1.68, P = 0.34).Our results confirm previous findings of increased chronic GVHD incidence in patients receiving PBSC when compared to patients receiving BM as the graft source in HSCT. Acute GVHD incidence, progression-free survival and overall survival were not different between the groups.

Cumulative incidence

10.1111/ejh.12508

Cite

Citations (18)

Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap

Blood (2011)

Dietger Niederwieser Helen Baldomero Michael Gratwohl Mahmoud Aljurf Luís Fernando Bouzas

10.1182/blood.v118.21.1016.1016

Cite

Citations (1)

Comparison of Mismatched Unrelated Donors and Cord Blood to Matched Unrelated Donors in pediatric patients with acute leukemias or myelodisplastic syndromes in Brazil: A multicenter retrospective study

Rita de Cássia Tavares M. E. Flowers Adriana Seber Carmem Bonfim Simone Pereira Lermontov

Cord blood

Hematology

Acute lymphocytic leukemia

Source

Cite

Citations (0)

Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome

BioMed Research International (2014)

Daiane Corrêa de Souza Cecília de Souza Fernandez Adriana Camargo Alexandre Gustavo Apa Elaine Sobral da Costa

We analyzed cytogenetically 105 patients with hypocellular primary MDS and their clinical implications. The main chromosomal abnormalities found were del(5q)/−5, del(6q)/+6, del(7q)/−7, del(11q), and del(17p). Pediatric patients had a higher frequency of abnormal karyotypes compared with adult patients (P< 0,05). From our patients, 18% showed evolution of the disease. The chromosomal abnormalities presented in the diagnosis of patients who evolved to AML included numerical (−7, +8) and structural del(6q), del(7q), i(7q), t(7;9), i(9q), and del(11q) abnormalities and complex karyotypes. Although the frequency of evolution from hypocellular MDS to AML is low, our results suggest that some chromosomal alterations may play a critical role during this process. We applied the IPSS in our patients because this score system has been proved to be useful for predicting evolution of disease. When we considered the patients according to group 1 (intermediate-1) and group 2 (intermediate-2 and high risk), we showed that group 2 had a high association with respect to the frequency of abnormal karyotypes (P< 0,0001), evolution of disease (P< 0,0001), and mortality (P< 0,001). In fact, the cytogenetic analysis for patients with hypocellular primary MDS is an important tool for diagnosis, prognosis, in clinical decision-making and in follow-up.

10.1155/2014/542395

Cite

Citations (14)

SUZ12 is a candidate target of the non‐canonical WNT pathway in the progression of chronic myeloid leukemia

Genes Chromosomes and Cancer (2009)

Luciana Pizzatti Renata Binato Jaime Cofré Bernadete Evangelho Gomes Jane Dobbin

Polycomb proteins form multiprotein complexes that repress target genes by chromatin remodeling. In this work, we report that the SUZ12 polycomb gene is over-expressed in bone marrow samples of patients at the blastic phase of chronic myeloid leukemia. We also found a direct interaction between polycomb group genes and the WNT signaling pathway in chronic myeloid leukemia transformation. Electrophoretic mobility shift assay (EMSA), Chromatin immunoprecipitation assay (ChIP), and mass spectrometry assays identified noncanonical WNT pathway members, such as WNT5A and WNT11, bound to the SUZ12 promoter. Immunohistochemistry and immunofluorescence with WNT5A and WNT11 antibodies confirmed nuclear localization. Knockdown of WNTs 1, 5A, and 11 with RNAi approaches showed that WNT members are capable of activating SUZ12 transcription with varying promoter affinities. Finally, we suggest that SUZ12 is blocking cellular differentiation, as SUZ12 knockdown release differentiation programs in chronic myeloid blastic phase (CML-BP) transformed cell line.

Non canonical

10.1002/gcc.20722

Cite

Citations (30)

One million haemopoietic stem-cell transplants: a retrospective observational study

The Lancet Haematology (2015)

Aloïs Gratwohl Marcelo C. Pasquini Mahmoud Aljurf Yoshiko Atsuta Helen Baldomero

10.1016/s2352-3026(15)00028-9

Cite

Citations (396)

COMPARATIVE ANALYSIS OF THE DATA ON THE INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE MARROW TRANSPLANTATION AND THE PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE 2020

JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (2020)

Fernando Barroso Duarte Anna Thawanny Gadelha Moura Abrahão Elias Hallack Neto Adriana Seber Afonso Celso Vigorito

This is an observational and cross-sectional study, carried out in May 2020, targeting adult individuals of both sexes who are members of multiprofessional teams working in Brazilian HSCT units in the current period of the pandemic by completing and analyzing a questionnaire. pre-formulated. HSCT units that cannot access the questionnaire were excluded from the study. The analysis of the operation profile of HSCT units in Brazil, through the application of a pre-structured questionnaire, is not an accurate tool, since it assumes some premises that may prove to be wrong, especially in this current scenario in Brazil. However, the data reveal the vulnerability of patients with onco-hematological diseases to infection by COVID-19, especially during HSCT procedures, in relation to the general population. Despite its limitations, it can be valuable to plan policies.

Pandemic

Vulnerability

10.46765/2675-374x.2020v2n1p63-68

Cite

Citations (1)

Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil

Pediatric Transplantation (2020)

Rita de Cássia Tavares Carmem Sales Bonfim Adriana Seber Simone Pereira Lermontov Vergilio Antonio Rensi Coulturato

Abstract The choice of alternative donors for HCT for patients without an HLA‐matched related donor depends on several factors. We compared major HCT outcomes in 212 consecutive children transplanted at 11 centers in Brazil for acute leukemia or MDS from an HLA‐matched unrelated donor (MUD, n = 95), mismatched unrelated donor (MMUD, n = 47) or unrelated umbilical cord blood (UCB, n = 70). Most had ALL (61%), bone marrow (57%) as the graft source and 95% received a MAC regimen. The 3‐year OS probability were 57, 55, and 37% after HCT from MUD, MMUD, and UCB, respectively (HR 1.68, 95%CI 1.07‐2.63; P = .02). In comparison with MUD, OS was similar after transplantation of a ≥ 6/8 HLA‐matched or a high cell dose (>5 × 10 7 TNC/kg) CB unit (HR 1.41, 95%CI 0.88‐2.27; P = .15). NRM was higher for UCB (HR 3.90, 95%CI 1.43‐10.7; P = .01) but not for MMUD (HR 1.03, 95%CI 0.53‐2.00; P > .20). Advanced disease (HR 2.05, 95%CI 1.26‐3.33; P < .001) and UCB with high probability of being < 6/8 HLA‐matched (HR 5.34, 95%CI 2.0‐13.9; P < .001) were associated with higher mortality. Relapse and acute GVHD were similar among groups, while PGF was higher among UCB transplants ( P = .002) and chronic GVHD among MMUD group (HR 2.88, 95% CI 1.05‐7.88; P = .04). Our results suggest that in Brazil HCT outcomes performed with MMUD and MUD donors were comparable, while with UCB units < 6/8 HLA‐matched were associated with higher NRM for children with acute leukemia or MDS.

Cord blood

Cumulative incidence

10.1111/petr.13789

Cite

Citations (8)